Lab Turnaround Time (TAT) Dashboard Template

Purpose and audience

This dashboard template helps laboratory, clinical, and operations teams reduce diagnostic delays that impact patient care by measuring specimen-to-result times, surfacing outliers, and directing practical actions. It is intended for lab managers, quality leads, clinical teams who depend on timely results, and analysts implementing the dashboard.

Primary hungers served

• Reduce lab delays that impact clinical decision-making.
• Reveal where and why tests are late so teams can fix root causes.
• Provide trusted, consistently defined TAT measures for accountability and improvement.

High-level pages and what they do

1. Executive snapshot — KPI cards showing median TAT, 90th-percentile TAT, percent within SLA (by priority group), volume trend, and a small sparkline of daily percent-within-SLA. Designed for quick health checks and executive huddles.
2. Detailed view — Breakdowns by test group (chemistry, hematology, microbiology, molecular), by test code, and by shift/operating period. Supports sorting and drill-down to individual runs and specimen events.
3. Specimen-source heatmap — Heatmap (ward/clinic × hour or shift) showing median or 90th-percentile TAT so teams can target process work in specific units or times.
4. Top delay reasons — Pareto of recorded delay causes (e.g., labeling errors, courier delays, instrument downtime, repeat testing, batching choices). Links to recent root-cause notes.
5. Outliers & daily operating checklist — Table of specimens outside SLA with quick action buttons and a linked daily checklist for managers to record immediate corrective steps. Checklist entries are time-stamped and stored for follow-up.

Key metrics and clear definitions

• Specimen-to-result TAT — primary measure. Base formula: result_time - collection_time (alternative: result_time - received_time depending on clinical need). Define start and stop consistently across the organization.
• Median TAT — the 50th percentile of specimen TATs in the selected timeframe. More robust than mean when distributions are skewed.
• 90th-percentile TAT — indicates tail behavior and risk of clinically important delays.
• Percent within SLA — count(TAT <= SLA_for_test_or_group) / total_count * 100. SLAs must be defined per test group and validated locally.
• Volume — total specimens / tests processed; monitor volume vs capacity.

Suggested visualizations

• KPI cards: median, 90th percentile, % within SLA (by priority), daily volume.
• Bar chart: median TAT by test group and by test code with percentile error bars (P10–P90).
• Heatmap: specimen source (ward/clinic) × hour/shift showing median or 90th percentile TAT.
• Boxplot or violin plot: distribution per test group to show spread and outliers.
• Pareto: cumulative percent of delay reasons to focus improvement effort.
• Outlier table: sortable list of specimens outside SLA with filters for priority, test, and location.

Filters and drill-downs

Provide filters for date range, test priority (STAT/routine), test group, ordering location, specimen type, shift (local shift definitions), instrument, and ordering provider. Drill from a test-group bar into the list of tests and then into individual specimen events.

Data requirements and mapping (minimum fields from LIS/EMR)

• accession_number (or unique specimen id)
• patient_id (de-identified when required)
• test_code / test_name / test_group
• collection_time (timestamp when specimen taken)
• received_time (timestamp when lab received specimen)
• result_time (timestamp when final result posted)
• result_status (final, preliminary, amended, cancelled, rejected)
• priority (STAT/routine/urgent)
• specimen_type/source (blood, CSF, sputum, etc.)
• ordering_location / ward / clinic
• instrument_id / analyzer
• rejection_reason or delay_reason (when available)

Calculation notes and data cleansing

Exclude cancelled or rejected tests from numerator/denominator. Decide how to treat partial results and amended results (record both original and final timestamps, but use consistent business rule). Normalize timezones and clock drift. Prefer median and percentile-based metrics over means when distributions are skewed.

Example metric pseudocode

Percent within SLA (per day, per test group):

SELECT test_group,
  COUNT(*) AS total,
  SUM(CASE WHEN (result_time - collection_time) <= sla_seconds THEN 1 ELSE 0 END) AS within_sla,
  (within_sla/total)*100 AS pct_within_sla
  FROM lab_events
  WHERE result_status = 'final' AND collection_time IS NOT NULL
  GROUP BY test_group;

Suggested thresholds and action triggers

• Alert when % within SLA for high-priority tests falls below agreed threshold (e.g., 95% — example only; set locally).
• Page lab leader when >X high-priority tests exceed SLA in a 1-hour window.
• Flag wards or shifts where median or 90th-percentile TAT exceeds baseline by defined margin for 3 consecutive days.

Outlier handling and daily operating checklist

Provide a prioritized table of specimens outside SLA with columns: accession, test, priority, collection_time, result_time, TAT, top delay reason, responsible owner. Link each outlier to a short daily operating checklist for immediate actions (e.g., confirm labeling, request courier pick-up, restart instrument, communicate to ordering clinician). Store checklist responses for audit and follow-up.

Implementation notes

• Automated data feeds from LIS and/or middleware are recommended for near-real-time monitoring. Define extract cadence (e.g., continuous, 15-min, hourly) based on use case.
• Agree on authoritative TAT start/stop timestamps and document definitions in the dashboard glossary.
• Map local test codes to standard test groups. Start with high-impact tests (troponin, CBC, BMP, blood cultures, respiratory PCR) and expand iteratively.
• Validate metrics by sampling records and reconciling with manual logs before making operational decisions.

Governance and ownership

• Assign a dashboard owner (lab quality lead) and data steward (IT/LIS analyst).
• Define refresh cadence, alert recipients, and escalation paths.
• Version control the mapping of tests to groups and SLA definitions; require change approvals.

How to tailor this template locally

Customize test-group definitions, SLA targets, shift windows, and delay-reason taxonomy to reflect local capacity, clinical priorities, and safety/regulatory constraints. Run a 30-day parallel validation before retiring existing manual reports.

Common pitfalls

• Mixing start-stop definitions across teams — leads to misleading comparisons.
• Using mean TAT for skewed distributions — conceals a long tail of delayed critical tests.
• Relying on a single unchecked SLA without clinical validation — may encourage unsafe workarounds.

Next steps

1. Confirm TAT definitions and SLAs with clinical stakeholders.
2. Establish data feed from LIS and perform data validation samples.
3. Deploy the executive snapshot and outlier table first, then add detailed views and heatmaps over time.
4. Use the dashboard in daily huddles and link the outlier checklist to accountability and improvement actions.